Toll-like receptor and antiphospholipid mediated thrombosis: In vivo studies

Annals of the Rheumatic Diseases

Volumn 66, Issue 10, 2007, Pages 1327-1333

  Pierangeli, Silvia S ^a   Vega Ostertag, Mariano E ^b   Raschi, Elena ^c   Liu, Xiaowei ^b   Romay Penabad, Zurina ^a   De Micheli, Valeria ^d   Galli, Monica ^e   Moia, Marco ^f   Tincani, Angela ^g   Borghi, Maria Orietta ^h   Nguyen Oghalai, Tracy ^a   Meroni, Pier Luigi ^h  

^a University of Texas Medical Branch School of Medicine   (United States)

^b MOREHOUSE SCHOOL OF MEDICINE   (United States)

^c ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^d A MANZONI HOSPITAL   (Italy)

^e OSPEDALI RIUNITI   (Italy)

^f FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^g Rheumatology and Clinical Immunology Service   (Italy)

^h UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPOLYSACCHARIDE; PHOSPHOLIPID ANTIBODY; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4;

ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

ADULT; ANIMALS; ANTIBODIES, ANTICARDIOLIPIN; ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; CELL ADHESION; ENDOTHELIAL CELLS; FEMALE; HUMANS; IMMUNOGLOBULIN G; LEUKOCYTES; MALE; MICE; MICE, INBRED C3H; POLYMORPHISM, GENETIC; THROMBOPHILIA; THROMBOPLASTIN; THROMBOSIS; TOLL-LIKE RECEPTOR 4;

EID: 34250721890     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.065037     Document Type: Article

References (48)

1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
2. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;335:1544-7.
3. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990;336:177-8.
4. 2glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990;87:4120-4.
5. Meroni PL, Raschi E, Testoni C, Borghi MO. Endothelial cell activation by antiphospholipid antibodies. Clin Immunol 2004;112:169-74.
6. 2glycoprotein I induce endothelial cell activation. Arthritis Rheum 1997;40:551-61.
7. Pierangeli SS, Colden-Stanfield M, Liu X, Barker JH, Anderson GH, Harris EN. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 1999;99:1997-2000.
8. Simantov E, LaSala J, Lo SK, Gharavi AE, Sammaritano LR, Salmon JE, et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995;96:2211-9.
9. Espinola RG, Liu X, Colden-Stanfield M, Hall J, Harris EN, Pierangeli SS. E-selectin mediated pathogenic effects of antiphospholipid antibodies. J Thromb Haemost 2002;1:843-8.
10. Meroni PL, E Raschi, C Testoni, A Tincani, G Balestrieri, R Molteni, et al. Statins prevent endothelial cell activation induced by anti-phospholipid (anti-β2 glycoprotein I) antibodies: effect on the pro-adhesive and pro-inflammatory phenotype. Arthritis Rheum 2001;44:2870-8.
11. Vega-Ostertag M, Casper K, Swerlick R, Ferrara D, Harris EN, Pierangeli SS. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum 2005;52:1545-54.
12. 2glycoprotein I antibodies. J Immunol 1998;160:5572-8.
13. 2glycoprotein I to human endothelial cells is mediated by annexin II. J Biol Chem 2000;275:15541-8.
14. 2glycoprotein I antibodies. Blood 2005;105:1964-9.
15. Raschi E, Testoni C, Bosisio D, Borghi MO, Koike T, Mantovani A, et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 2003;101:3495- 500.
16. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001;2:675-80.
17. Kawai T, Akira S. Toll-like receptor downstream signalling. Arthritis Res Ther 2005;7:12-9.
18. Beutler B, Du X, Poltorak A. Identification of Toll-like receptor 4 (TLR-4) as the sole conduit for LPS signal transduction: genetic and evolutionary studies. J Endotoxin Res 2001;7:277-80.
19. Akira S, Takeda K. Functions of toll-like receptors: lessons from KO mice. CR Biol 2004;327:581-9.
20. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, et al. Cutting edge: Toll-like receptor 4 (TLR-4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR-4 as the LPS gene product. J Immunol 1999;162:3749-52.
21. Kmonickiva E, Zldek Z. Quantitative aspects of lipopolysaccharide and cytokine rrequirements to generate nitric oxide in macrophages from LPS-hyporesponsive (Lps(d)) C3H/HeJ mice. Folia Microbiol 2004;49:737-44.
22. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000;25:187-91.
23. Schröder NWJ, Schumann RR. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis, 2005;5:156-64.
24. Fageras-Bottcher M, Hmani-Aifa M, Lindstrom A, Jenmalm MC, Mai XM, Nilsson L, et al. A TLR4 polymorphism is associated with asthma and reduced lipopolysaccharide-induced interleukin-12(p70) responses in Swedish children. J Allergy Clin Immunol 2004;114:561-7.
25. Pierangeli SS, Liu XW, Anderson GH, Barker JH, Harris EN. Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome. Thromb Haemost 1995;74:1361-7.
26. 2- glycoprotein I is complement-dependent and requires a priming factor. Blood 2005;106:2340-6.
27. Bradford MM. A refined and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Ann Biochem 1976;72:248-54.
28. Day SM, Reeve JL, Pedersen B, Farris DM, Myers DD, Im M, et al. Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. Blood 2005;105:192-8.
29. Lorenz E, Frees KL, Schwartz DA. Determination of the TLR-4 genotype using allele-specific PCR. Biotechniques 2001;31:22-4.
30. Cesarman-Maus G, Rios-Luna NP, Deora AB, Villa R, Craviolo MC, Alarcon-Segovia D, et al. Autoantibodies against the fibrinolytic receptorm annexin 2, in antiphospholipid syndrome. Blood 2006;107:4375-82.
31. 2GPI) antibodies is mediated by annexin II cross linking and may involve TLR-4 (abstract). Blood 2004;104:83.
32. 2- glycoprotein I and preserved during species evolution. J Immunol 1996;157:5732-8.
33. Salmon JE, Girardi G, Holers VM. Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis. Ann Rheum Dis 2002;61:46-50.
34. Girardi G, Berman J, Redecha P, Spruce L, Thurman J, Young K, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphophospholipid syndrome. J Clin Invest 2003;112:1644-54.
35. Girardi G, Redecha P, Salmon J. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004;10:1222.
36. Pierangeli SS, Girardi G, Vega-Ostertag ME, Liu X, Espinola RG, Salmon J. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005;52:2120-4.
37. Ikeda K, Nagasawa K, Horiuchi T, Tsuru T, Nishizaka H, Niho Y. C5a induces tissue factor activity on endothelial cells. Thromb Haemost 1997;77:394-8.
38. Hattori E, Hamilton KK, McEver RP, Sims PJ. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem 1989;264:9053-60.
39. Fischetti F, Tedesco F. Cross-talk between the complement system and endothelial cells in physiologic conditions and in vascular diseases. Autoimmunity 2006;39:417-28.
40. Huber-Lang M, Sarma JV, Zetoune FS, Rittisrch D, Neff TA, McGuire SR, et al. Generation of C5a in the absence of C3: a new complement activation pathway. Not Med 2006;12:682-7.
41. Cook DN, Pisetsky DS, Schwartz DA. Toll-like receptors in the pathogenesis of human disease. Nat Immunol 2004;5:975-9.
42. Erridge C, Stewart J, Poxton IR. Monocytes heterozygous for the Asp299Gly and Thr399Ile mutations in the Toll-like receptor 4 gene show no deficit in lipopolysaccharide signalling. J Exp Med 2003;197:1787- 91.
43. von Aulock S, Schroder NW, Gueinzius K, Traub S, Hoffmann S, Graf K, et al. Heterozygous toll-like receptor 4 polymorphism does not influence lipopolysaccharide-induced cytokine release in human whole blood. J Infect Dis 2003;188:938-43.
44. van der Graaf C, Kullberg BJ, Joosten L, Verver-Jansen T, Jacobs L, Van der Meer JW, et al. Functional consequences of the Asp299Gly Toll-like receptor-4 polymorphism. Cytokine 2005;30:264-8.
45. Pasterkamp G, van Keulen JK, de Kleijn DVP. Role of Toll-like receptor 4 in the initiation and progression of atherosclerotic disease. Eur J Clin Invest 2004;34:328-34.
46. Fox EA, Kahn SR. The relationship between inflammation and venous thrombosis. Thromb Haemost 2005;94:362-5.
47. Rossignol DP, Lynn M. TLR-4 antagonists for endotoxemia and beyond. Curr Opin Invest Drugs 2005;6:496-502.
48. 2glycoprotein I reverses antiphospholipid- mediated thrombosis. Lupus 2006;15:358-65.